Pandorum Technologies Raises $18 Mn to Scale Regenerative Therapies Globally

The transaction was advised by Bandana Kankani, advisor and investor at Pandorum. The company did not disclose its post-money valuation.

Pandorum Technologies, a Bengaluru-based biotechnology company working in programmable regenerative medicine, has closed an $18 million Series B funding round to advance clinical development of its exosome-based therapies and expand its global manufacturing and operational footprint.

The financing round was led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, the Burman Family, and other investors. 

The transaction was advised by Bandana Kankani, advisor and investor at Pandorum. The company did not disclose its post-money valuation.

Pandorum stated that the capital will be used to progress its disease-modifying, tunable regenerative therapies through clinical development, scale manufacturing capabilities, and increase market access across key regions, including the United States, Japan, and the Middle East. The funding will also support the expansion of operational teams in these geographies.

Founded by Tuhin Bhowmick and Arun Chandru, Pandorum operates across India and the United States and focuses on developing programmable, regenerative therapies using exosomes. Its platform integrates biological systems, engineering approaches, and computational models to design therapies aimed at reprogramming pathological tissue states such as inflammation and fibrosis toward functional recovery.

The company has adopted a globally distributed manufacturing strategy to support its clinical and commercial programs. For the US and European markets, Pandorum has partnered with AGC Biologics in Italy as its contract development and manufacturing organization. In India and the broader Asia-Pacific region, it has entered into a strategic collaboration with Nucelion Therapeutics, a subsidiary of Bharat Biotech. The company is also evaluating additional manufacturing and distribution partnerships in the Middle East.

Pandorum’s lead therapeutic focus is in ophthalmology, particularly ocular surface disorders such as Stevens–Johnson Syndrome and Neurotrophic Keratitis. Its lead candidate, Kuragenx, has received Orphan Drug Designation from the US Food and Drug Administration for these indications. The company is continuing clinical development activities to support future regulatory pathways in the US and other markets.

Beyond ophthalmology, Pandorum is expanding its tunable regenerative platform to address systemic inflammatory and degenerative conditions affecting organs such as the lung, liver, and nervous system. The company indicated that further clinical programs in these areas are under development as part of its broader pipeline strategy.

Stay tuned for more such updates on Digital Health News